Exondys 51 Reviewers
FDA staff who participated in the review of Sarepta's Duchenne muscular dystrophy drug eteplirsen.
You may also be interested in...
Pink Sheet’s Drug Review Profile looks at US FDA clinical memos opposing approval of Sarepta's Duchenne muscular dystrophy drug eteplirsen, revealing challenges patient advocates and agency face in transforming patient experiences into hard data that can be used for approvals.
There is anxiety within the US agency over use of the pathway amid the prospect for confirmatory trials to fail, former CEO Garabedian says at FDA/CMS Summit.
Chronicle of the development and FDA review of Sarepta's eteplirsen for Duchenne muscular dystrophy.